Literature DB >> 27513084

Simvastatin Attenuates Acute Lung Injury via Regulating CDC42-PAK4 and Endothelial Microparticles.

Yang Yu1, Lihong Jing, Xiangyu Zhang, Chengjin Gao.   

Abstract

BACKGROUND: Simvastatin has lung vascular-protective effects via augmentation of endothelial barrier function. Accordingly, on the basis of our previous study, we hypothesized that endothelial cell (EC) protection by simvastatin is dependent on the stabilization on cytoskeletons.
METHODS: Sixty C57BL/6 mice were divided into two experimental groups: lipopolysaccharide (LPS) group (L group) and LPS+simvastatin treated group (L+S group). All mice in these two groups received an intraperitoneal injection of LPS (10 mg/kg/d). Simvastatin was administered intraperitoneally immediately after the LPS injection in animals of the L+S group at a dose of 20 mg/kg/day. Lung injury degree and the protective effects of simvastatin against LPS-induced lung injury were assessed at the time-points of 24, 48, and 72 h postinjection. Serum alanine transaminase (ALT), serum creatinine (Scr) were identified to assess the hepatic and renal side-effects of simvastatin.
RESULTS: LPS inhibited the cytoskeletal regulating proteins of Cdc42 and PAK4, and was accompanied by an increased circulating endothelial microparticles (EMPs) level. The adherent junction (AJ) protein of VE-cadherin was also decreased by LPS, and was accompanied by a thickening alveolar wall, increased lung W/D values, and high albumin concentration in bronchoalveolar lavage. Protective effects of simvastatin against LPS-induced lung injury were illustrated by regulating and stabilizing cytoskeletons, as well as intercellular AJs. The values of ALT and Scr were all lower than the common upper limits according to assay kits.
CONCLUSION: An increased serous EMP level associated with Cdc42-PAK4 can be deemed as a useful pulmonary injury marker in LPS-treated mice, and our results might be more relevant in guiding the clinical treatment of ALI by intervening Cdc42-PAK4 or EMPs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27513084     DOI: 10.1097/SHK.0000000000000723

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  10 in total

1.  Anti-inflammatory Effects of Statins in Lung Vascular Pathology: From Basic Science to Clinical Trials.

Authors:  Reem Faraj; Danyelle Paine; Stephen M Black; Ting Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Extracellular Vesicles: A New Frontier for Research in Acute Respiratory Distress Syndrome.

Authors:  Rahul Y Mahida; Shotaro Matsumoto; Michael A Matthay
Journal:  Am J Respir Cell Mol Biol       Date:  2020-07       Impact factor: 6.914

3.  ROS-responsive polymer nanoparticles with enhanced loading of dexamethasone effectively modulate the lung injury microenvironment.

Authors:  Wali Muhammad; Jiaqi Zhu; Zihe Zhai; Jieqi Xie; Jiahang Zhou; Xudong Feng; Bing Feng; Qiaoling Pan; Shifen Li; Rajiu Venkatesan; Pan Li; Hongcui Cao; Changyou Gao
Journal:  Acta Biomater       Date:  2022-06-18       Impact factor: 10.633

4.  Endothelial Extracellular Vesicles in Pulmonary Function and Disease.

Authors:  Eleftheria Letsiou; Natalie Bauer
Journal:  Curr Top Membr       Date:  2018-10-08       Impact factor: 3.049

5.  Simvastatin Ameliorates PAK4 Inhibitor-Induced Gut and Lung Injury.

Authors:  Shuming Pan; Zengbin Wu; Xuan Liu; Jiameng Chen; Huiqi Wang; Dan Liu; Aihua Fei; Liang Chen; Chengjin Gao
Journal:  Biomed Res Int       Date:  2017-12-28       Impact factor: 3.411

Review 6.  Extracellular vesicles: novel communicators in lung diseases.

Authors:  Aradhana Mohan; Stuti Agarwal; Matthias Clauss; Nicholas S Britt; Navneet K Dhillon
Journal:  Respir Res       Date:  2020-07-08

Review 7.  Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options.

Authors:  Trushil G Shah; Dan Predescu; Sanda Predescu
Journal:  Clin Transl Med       Date:  2019-09-12

8.  Blood CDC42 overexpression is associated with an increased risk of acute exacerbation, inflammation and disease severity in patients with chronic obstructive pulmonary disease.

Authors:  Xiaoyan Ming; Fan Yang; Hong Zhu
Journal:  Exp Ther Med       Date:  2022-06-30       Impact factor: 2.751

9.  PAK4 suppresses TNF-induced release of endothelial microparticles in HUVECs cells.

Authors:  Shouqin Zhang; Yingjie Yin; Congye Li; Yi Zhao; Qixing Wang; Xiangyu Zhang
Journal:  Aging (Albany NY)       Date:  2020-07-12       Impact factor: 5.682

10.  Vimentin as a target for the treatment of COVID-19.

Authors:  Zhenlin Li; Denise Paulin; Patrick Lacolley; Dario Coletti; Onnik Agbulut
Journal:  BMJ Open Respir Res       Date:  2020-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.